Search Results
You are looking at 11 - 16 of 16 items for :
- Abstract: adrenarche x
- Abstract: amenorrhoea x
- Abstract: fertility x
- Abstract: Hypogonadism x
- Abstract: infertility x
- Abstract: Kallmann x
- Abstract: Klinefelter x
- Abstract: menarche x
- Abstract: menopause x
- Abstract: puberty x
- Abstract: testes x
- Abstract: transsexual x
- Abstract: Turner x
- Abstract: ovary x
- Abstract: follicles x
- Pituitary and Hypothalamus x
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jesper Krogh in
Google Scholar
PubMed
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Peter Plomgaard in
Google Scholar
PubMed
Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Ruth Frikke-Schmidt in
Google Scholar
PubMed
Search for other papers by Sten Velschow in
Google Scholar
PubMed
Department of Pediatrics, Copenhagen University Hospital - Herlev & Gentofte, Copenhagen, Denmark
Search for other papers by Jesper Johannesen in
Google Scholar
PubMed
Search for other papers by Linda Maria Hilsted in
Google Scholar
PubMed
Search for other papers by Malene Schrøder in
Google Scholar
PubMed
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Repeated blood sampling is required in certain clinical and research settings, which is currently performed by drawing blood from venous catheters requiring manual handling of each sample at the time of collection. A novel body-worn device for repeated serial samples, Fluispotter®, with automated extraction, collection, and storage of up to 20 venous dried blood spot samples over the course of 20 h may overcome problems with current methods for serial sampling. The purpose of this study was to assess the performance and safety of Fluispotter for the first time in healthy subjects. Fluispotter consists of a cartridge with tubing, a reservoir for flushing solution, pumps and filterpaper, and a multi-lumen catheter placed in the brachial vein. We recruited healthy subjects for testing in an in-hospital setting. Fluispotter was attached by an anesthesiologist to 22 healthy subjects of which 9/22 (40.9%) participants had all 20 samples taken, which was lower than the goal of complete sampling in 80% of the subjects (P = 0.02). The main reason for sample failure was clogging of blood flow which was observed in 11/22 (50%) of the participants. No serious adverse events occurred, and the participants rated the pain from the insertion and the removal of catheter as very low. A cortisol profile showed nadir values at midnight and highest values at 05:00 h. Although full sampling was not successful in all participants, the Fluispotter technology proved safe and highly acceptable to the participants producing the expected cortisol profile without the requirement of staff during sample collection.
Search for other papers by Jiaxi Li in
Google Scholar
PubMed
Search for other papers by Pu Huang in
Google Scholar
PubMed
Search for other papers by Jing Xiong in
Google Scholar
PubMed
Search for other papers by Xinyue Liang in
Google Scholar
PubMed
Search for other papers by Mei Li in
Google Scholar
PubMed
Search for other papers by Hao Ke in
Google Scholar
PubMed
Search for other papers by Chunli Chen in
Google Scholar
PubMed
Search for other papers by Yang Han in
Google Scholar
PubMed
Search for other papers by Yanhong Huang in
Google Scholar
PubMed
Search for other papers by Yan Zhou in
Google Scholar
PubMed
Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, Hunan, China
Search for other papers by Ziqiang Luo in
Google Scholar
PubMed
Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, Hunan, China
Search for other papers by Dandan Feng in
Google Scholar
PubMed
Search for other papers by Chen Chen in
Google Scholar
PubMed
Objective
Ghrelin regulates body weight, food intake, and blood glucose. It also regulates insulin secretion from pancreatic islet cells. LEAP2 is a newly discovered endogenous ligand of the growth hormone secretagogue’s receptor (GHSR). It not only antagonizes the stimulation of GHSR by ghrelin but also inhibits the constitutive activation of GHSR as an inverse agonist. Type 2 diabetes (T2D) patients have endocrine disorders with metabolic imbalance. Plasma levels of ghrelin and LEAP2 may be changed in obese and T2D patients. However, there is no report yet on circulating LEAP2 levels or ghrelin/LEAP2 ratio in T2D patients. In this study, fasting serum ghrelin and LEAP2 levels in healthy adults and T2D patients were assessed to clarify the association of two hormones with different clinical anthropometric and metabolic parameters.
Design
A total of 16 females and 40 males, ages 23–68 years old normal (n = 27), and T2D patients (n = 29) were enrolled as a cross-sectional cohort.
Results
Serum levels of ghrelin were lower but serum levels of LEAP2 were higher in T2D patients. Ghrelin levels were positively correlated with fasting serum insulin levels and HOMA-IR in healthy adults. LEAP2 levels were positively correlated with age and hemoglobin A1c (HbA1c) in all tested samples. Ghrelin/LEAP2 ratio was negatively correlated with age, fasting blood glucose, and HbA1c.
Conclusions
This study demonstrated a decrease in serum ghrelin levels and an increase in serum LEAP2 levels in T2D patients. LEAP2 levels were positively correlated with HbA1c, suggesting that LEAP2 was associated with T2D development. The ghrelin/LEAP2 ratio was closely associated with glycemic control in T2D patients showing a negative correlation with glucose and HbA1c.
Search for other papers by Vanderlan O Batista in
Google Scholar
PubMed
Search for other papers by Michael Kellner in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Walter Lisboa in
Google Scholar
PubMed
Search for other papers by André Faro in
Google Scholar
PubMed
Search for other papers by Lucas B Santos in
Google Scholar
PubMed
Search for other papers by Enaldo V Melo in
Google Scholar
PubMed
Search for other papers by Alécia A Oliveira-Santos in
Google Scholar
PubMed
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Search for other papers by Cynthia S Barros-Oliveira in
Google Scholar
PubMed
Search for other papers by Elenilde G Santos in
Google Scholar
PubMed
Search for other papers by Nathalie O Santana in
Google Scholar
PubMed
Search for other papers by Keila R Villar-Gouy in
Google Scholar
PubMed
Search for other papers by Ângela C Leal in
Google Scholar
PubMed
Search for other papers by Rivia S Amorim in
Google Scholar
PubMed
Search for other papers by Davi A Oliveira Simões in
Google Scholar
PubMed
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
Individuals with untreated isolated GH deficiency (IGHD) due to a mutation in the GHRH receptor gene from Itabaianinha Brazil have increased insulin sensitivity, normal life expectancy, and an extended health span, i.e. the period of life free from disabilities. We hypothesize that their prolonged health span is accompanied by a delayed cognitive decline in senescence. To test this hypothesis, we have administered the Literacy-Independent Cognitive Assessment (LICA) to 15 IGHD individuals aged over 50 years and 15 controls matched by age, sex, years of education, and percentage of illiteracy. All individuals were negative for HIV and syphilis serology, and there were no differences in serum levels of folate, vitamin B12 and TSH between the two groups, while free T4 was higher in the IGHD group. IGHD subjects had a higher total LICA score than controls, 215 (22.7) vs 204.2 (18.1), without reaching statistical significance. Scores of memory, visuoconstruction, language and calculation were similar between the two groups, with better attention (9.5 (1.4) vs 8.3 (1.1), P = 0.01) and executive function (38.3 (4.8) vs 35.1 (2.5), P = 0.03) scores in IGHD. MANCOVA revealed that group (but no age) had a significant effect on the LICA variables (partial eta squared of 0.455, power of 0.812, P = 0.02). This effect is verified on attention (partial eta squared 0.216, power of 0.749, P = 0.01) and executive function (partial eta squared 0.154, power of 0.570, P = 0.03. In conclusion, IGHD in senescence is associated with similar total cognitive performance but better attention and executive function than controls.
Division of Endocrinology, Mid and South Essex NHS Trust, Broomfield, UK
Search for other papers by Saroj Kumar Sahoo in
Google Scholar
PubMed
Search for other papers by Jayakrishnan C Menon in
Google Scholar
PubMed
Search for other papers by Nidhi Tripathy in
Google Scholar
PubMed
Search for other papers by Monalisa Nayak in
Google Scholar
PubMed
Search for other papers by Subhash Yadav in
Google Scholar
PubMed
Objective
We studied the temporal course of hypothalamic–pituitary–adrenal (HPA) dysfunction in patients with coronavirus disease 2019 (COVID-19).
Methods
Three hundred and two patients (median age 54 years (interquartile range (IQR) 42–64), 76% males) were recruited. The HPA axis was evaluated by morning cortisol and adrenocorticotrophic hormone (ACTH) at admission (n = 232). Adrenal insufficiency (AI) during acute illness was defined using a morning cortisol <83 nmol/L. AI at 12 months follow-up was defined using a peak cortisol <406 nmol/L in the ACTH stimulation test (APST) (n = 90). Those with AI at 12 months were further assessed by APST every 6 months for recovery of hypoadrenalism.
Results
The median morning cortisol and ACTH levels during COVID-19 were 295 (IQR 133–460) nmol/L and 3.9 (0.8–6.9) pmol/L, respectively. AI was present in 33 (14%) patients; ACTH was elevated in three and low or inappropriately normal in the rest 30 patients. At 12 months, AI was seen in 13% (12/90) patients, with all cases being hypothalamic–pituitary in origin; five (42%) of them had not met the diagnostic criteria for AI during COVID-19. AI diagnosed at admission persisted at 12 months in seven patients and recovered in seven; the remaining 19 patients were lost to follow-up. The presence of AI at 12 months was independent of severity and steroid use during COVID-19. A morning cortisol <138 nmol/L during COVID-19 predicted the presence of AI at 12 months. All patients showed recovery of the HPA axis in the ensuing 12 months.
Conclusion
Central AI was common during acute COVID-19 and at 12 months of follow-up. AI can be late onset, developing after recovery from COVID-19, and was transient in nature.
Search for other papers by Antonella Giampietro in
Google Scholar
PubMed
Search for other papers by Sabrina Chiloiro in
Google Scholar
PubMed
Search for other papers by Claudio Urbani in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Martin Ove Carlsson in
Google Scholar
PubMed
Search for other papers by Francesca Dassie in
Google Scholar
PubMed
Search for other papers by Nunzia Prencipe in
Google Scholar
PubMed
Search for other papers by Marta Ragonese in
Google Scholar
PubMed
Search for other papers by Roy Gomez in
Google Scholar
PubMed
Search for other papers by Simona Granato in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavò in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Pietro Maffei in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
Purpose
The aim of this study was to examine the probability of achieving acromegaly disease control according to several patient-, disease- and treatment-related factors longitudinally.
Methods
We analyzed data from ACROSTUDY, an open-label, noninterventional, post-marketing safety surveillance study conducted in 15 countries. A total of 1546 patients with acromegaly and treated with pegvisomant, with available information on baseline IGF-1 level, were included. Factors influencing IGF-1 control were assessed up to 10 years of follow-up by mixed-effects logistic regression models, taking into account changing values of covariates at baseline and at yearly visits. Twenty-eight anthropometric, clinical and treatment-related covariates were examined through univariate and multivariate analyses. We tested whether the probability of non-control was different than 0.50 (50%) by computing effect sizes (ES) and the corresponding 95% CI.
Results
Univariate analysis showed that age <40 years, normal or overweight, baseline IGF-1 <300 µg/L or ranged between 300 and 500 µg/L, and all pegvisomant dose <20 mg/day were associated with a lower probability of acromegaly uncontrol. Consistently, in multivariate analyses, the probability of uncontrolled acromegaly was influenced by baseline IGF-1 value: patients with IGF-1 <300 µg/L had the lowest risk of un-controlled acromegaly (ES = 0.29, 95% CI: 0.23–0.36). The probability of acromegaly uncontrol was also lower for values 300–500 µg/L (ES = 0.37, 95% CI: 0.32–0.43), while it was higher for baseline IGF-1 values ≥700 µg/L (ES = 0.58, 95% CI: 0.53–0.64).
Conclusion
Baseline IGF-l levels were a good predictor factor for long-term acromegaly control. On the contrary, our data did not support a role of age, sex, BMI and pegvisomant dose as predictors of long-term control of acromegaly.
Significance statement
Among factors that could influence and predict the efficacy of pegvisomant therapy in controlling acromegaly, a central role of baseline IGF-1 values on the probability of achieving a biochemical control of acromegaly during the treatment with pegvisomant was identified, in a real-life setting.
Search for other papers by Ja Hye Kim in
Google Scholar
PubMed
Search for other papers by Yunha Choi in
Google Scholar
PubMed
Search for other papers by Soojin Hwang in
Google Scholar
PubMed
Search for other papers by Ji-Hee Yoon in
Google Scholar
PubMed
Search for other papers by Jieun Lee in
Google Scholar
PubMed
Search for other papers by Min Jae Kang in
Google Scholar
PubMed
Search for other papers by Gu-Hwan Kim in
Google Scholar
PubMed
Search for other papers by Han-Wook Yoo in
Google Scholar
PubMed
Search for other papers by Jin-Ho Choi in
Google Scholar
PubMed
Objective
This study was performed to investigate the molecular characteristics and frequency of copy number variations (CNVs) of ANOS1 in patients with Kallmann syndrome (KS) or normosmic isolated hypogonadotropic hypogonadism (nIHH) using multiplex ligation-dependent probe amplification (MLPA) analysis and sequencing.
Methods
Among 45 patients from 43 independent families, Sanger sequencing, next-generation sequencing (NGS), or microarray was performed in 24 patients from 23 families, and MLPA was performed in 19 patients who did not show rare sequence variants (n = 18) or ANOS1 amplification by PCR (n = 1).
Results
Seven patients (four patients with KS, one patient with nIHH, one prepubertal boy with anosmia, and one newborn patient) from six families (6/43, 14%) harbored molecular defects in ANOS1 including a nonsense mutation (c.1140G>A (p.W380*)), a frameshift mutation (c.1260del (p.Q421Kfs*61)), a splice site mutation (c.1449+1G>A), an exon 7 deletion, a complete deletion, and 7.9 Mb-sized inversion encompassing ANOS1. The complete deletion of ANOS1 was identified in a neonate with a micropenis and cryptorchidism. Unilateral renal agenesis was found in three patients, whereas only one patient displayed both synkinesia and sensorineural hearing loss. There was no reversal of hypogonadotropic hypogonadism in any patient during 9.1 ± 2.9 years of treatment with testosterone enanthate.
Conclusions
Molecular defects in the ANOS1 gene could be identified in 14% of probands including various types of CNVs (3/43, 7.0%). Comprehensive analysis using sequencing and analysis for CNVs is required to detect molecular defects in ANOS1.